Literature DB >> 25082787

The challenge of cross-trial comparisons using limited data.

Jacob P Laubach1, Edward A Faber2, Peter Voorhees3, Javid Moslehi4, Cindy Varga1, Liviu Niculescu5, Kenneth C Anderson1, Paul G Richardson6.   

Abstract

Keywords:  challenge; cross-trial; data

Mesh：

Substances：

Year:  2014        PMID： 25082787      PMCID： PMC4116848          DOI： 10.3324/haematol.2013.103135

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

2.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

3.  An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Authors:  Ravi Vij; Michael Wang; Jonathan L Kaufman; Sagar Lonial; Andrzej J Jakubowiak; A Keith Stewart; Vishal Kukreti; Sundar Jagannath; Kevin T McDonagh; Melissa Alsina; Nizar J Bahlis; Frederic J Reu; Nashat Y Gabrail; Andrew Belch; Jeffrey V Matous; Peter Lee; Peter Rosen; Michael Sebag; David H Vesole; Lori A Kunkel; Sandra M Wear; Alvin F Wong; Robert Z Orlowski; David S Siegel
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

4.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

5.  An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Authors:  Ravi Vij; David S Siegel; Sundar Jagannath; Andrzej J Jakubowiak; Alexander Keith Stewart; Kevin McDonagh; Nizar Bahlis; Andrew Belch; Lori A Kunkel; Sandra Wear; Alvin F Wong; Michael Wang
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

6.  An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Authors:  Sundar Jagannath; Ravi Vij; A Keith Stewart; Suzanne Trudel; Andrzej J Jakubowiak; Tony Reiman; George Somlo; Nizar Bahlis; Sagar Lonial; Lori A Kunkel; Alvin Wong; Robert Z Orlowski; David S Siegel
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10

7.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

8.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Authors:  David Siegel; Thomas Martin; Ajay Nooka; R Donald Harvey; Ravi Vij; Ruben Niesvizky; Ashraf Z Badros; Sundar Jagannath; Leanne McCulloch; Kanya Rajangam; Sagar Lonial
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors:  Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113
View more
  2 in total

1.  Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000.

Authors:  David S Siegel
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

2.  Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.

Authors:  Philippe Moreau; Keith A Stewart; Meletios Dimopoulos; David Siegel; Thierry Facon; James Berenson; Noopur Raje; Jesus G Berdeja; Robert Z Orlowski; Hui Yang; Haijun Ma; Zandra Klippel; Anita Zahlten-Kumeli; Khalid Mezzi; Karim Iskander; Maria-Victoria Mateos
Journal:  Cancer Med       Date:  2020-02-28       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.